NYSE:PFE - Pfizer Stock Price, News & Analysis

$36.96
+0.05 (+0.14 %)
(As of 09/16/2019 10:26 AM ET)
Today's Range
$36.35
Now: $36.9550
$36.9856
50-Day Range
$34.14
MA: $36.70
$43.09
52-Week Range
$33.97
Now: $36.9550
$46.47
Volume2.07 million shs
Average Volume20.09 million shs
Market Capitalization$204.40 billion
P/E Ratio12.32
Dividend Yield3.86%
Beta0.65
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP71708110
Phone212-733-2323

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$53.65 billion
Cash Flow$4.1757 per share
Book Value$11.03 per share

Profitability

Net Income$11.15 billion

Miscellaneous

Employees92,400
Outstanding Shares5,531,050,000
Market Cap$204.40 billion
Next Earnings Date10/29/2019 (Estimated)
OptionableOptionable

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.


Pfizer (NYSE:PFE) Frequently Asked Questions

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer announced a quarterly dividend on Thursday, June 27th. Shareholders of record on Friday, August 2nd will be paid a dividend of $0.36 per share on Tuesday, September 3rd. This represents a $1.44 dividend on an annualized basis and a yield of 3.90%. The ex-dividend date is Thursday, August 1st. View Pfizer's Dividend History.

How will Pfizer's stock buyback program work?

Pfizer declared that its Board of Directors has authorized a stock buyback program on Friday, December 14th 2018, which allows the company to repurchase $10,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy up to 3.8% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's board of directors believes its shares are undervalued.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) posted its quarterly earnings data on Monday, July, 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.75 by $0.05. The biopharmaceutical company had revenue of $13.26 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The firm's revenue for the quarter was down 1.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.77 EPS. View Pfizer's Earnings History.

When is Pfizer's next earnings date?

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Pfizer.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer issued an update on its FY19 earnings guidance on Monday, July, 29th. The company provided EPS guidance of $2.76-2.86 for the period, compared to the Thomson Reuters consensus estimate of $2.91. The company issued revenue guidance of $50.5-52.5 billion, compared to the consensus revenue estimate of $53.45 billion.

What price target have analysts set for PFE?

17 Wall Street analysts have issued 12 month target prices for Pfizer's shares. Their predictions range from $36.00 to $55.00. On average, they anticipate Pfizer's stock price to reach $45.8750 in the next twelve months. This suggests a possible upside of 24.4% from the stock's current price. View Analyst Price Targets for Pfizer.

What is the consensus analysts' recommendation for Pfizer?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 13 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pfizer.

What are Wall Street analysts saying about Pfizer stock?

Here are some recent quotes from research analysts about Pfizer stock:
  • 1. According to Zacks Investment Research, "Pfizer expects continued strong growth of key product franchises, including Ibrance, Eliquis, Xeljanz and Xtandi in 2019. However, loss of exclusivity on key drugs in the United States., mainly Lyrica and currency headwinds are expected to significantly hurt its 2019 sales. Other top-line headwinds are weak sales in the EH segment, pricing pressure and rising competition. To offset the threat of generic competition, Pfizer is strengthening its pipeline as well as oncology portfolio. Pfizer looks well positioned to deliver several potential new breakthrough innovative medicines in the next five years, which can drive long-term growth. Biosimilars are also expected to contribute to growth in 2019. Shares have underperformed the industry this year so far. Estimates have gone down slightly ahead of Q1 earnings release. Pfizer has a positive record of earnings surprises in recent quarters." (4/10/2019)
  • 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and think respectable earnings growth, driven by Innovative Medicines, pipeline advancements, and return of capital to PFE’s shareholders — above the industry average — are all underappreciated. Therefore, we believe multiple expansion and upward earnings revisions should drive PFE shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $53." (2/19/2019)

Has Pfizer been receiving favorable news coverage?

News headlines about PFE stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pfizer earned a coverage optimism score of 0.9 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Pfizer.

Are investors shorting Pfizer?

Pfizer saw a decrease in short interest in August. As of August 31st, there was short interest totalling 55,228,300 shares, a decrease of 18.7% from the July 31st total of 67,951,100 shares. Based on an average trading volume of 25,340,000 shares, the days-to-cover ratio is currently 2.2 days. Approximately 1.0% of the shares of the stock are sold short. View Pfizer's Current Options Chain.

Who are some of Pfizer's key competitors?

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Cisco Systems (CSCO), Johnson & Johnson (JNJ), General Electric (GE), Verizon Communications (VZ), Intel (INTC), Exxon Mobil (XOM), Bank of America (BAC), Merck & Co., Inc. (MRK) and Walt Disney (DIS).

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:
  • Mr. Ian C. Read, Exec. Chairman (Age 65)
  • Mr. Albert Bourla D.V.M., DVM, Ph.D., CEO & Director (Age 57)
  • Mr. Frank A. D'Amelio, CFO & EVP of Global Supply & Bus. Operations (Age 61)
  • Dr. Mikael Dolsten, Chief Scientific Officer & Pres of Worldwide Research, Devel. and Medical (Age 60)
  • Mr. John D. Young, Group Pres & Chief Bus. Officer (Age 54)

Who are Pfizer's major shareholders?

Pfizer's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.01%), Price T Rowe Associates Inc. MD (1.69%), Northern Trust Corp (1.37%), Bank of New York Mellon Corp (1.06%), Morgan Stanley (0.84%) and Fisher Asset Management LLC (0.79%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Charles H Hill, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Sally Susman, Scott Gottlieb and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

Which institutional investors are selling Pfizer stock?

PFE stock was sold by a variety of institutional investors in the last quarter, including Barrow Hanley Mewhinney & Strauss LLC, Barrow Hanley Mewhinney & Strauss LLC, Price T Rowe Associates Inc. MD, Marshall Wace North America L.P., AQR Capital Management LLC, Quest Capital Management Inc. ADV, Vanguard Group Inc. and Acadian Asset Management LLC. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Mikael Dolsten and Rady A Johnson. View Insider Buying and Selling for Pfizer.

Which institutional investors are buying Pfizer stock?

PFE stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Natixis, Natixis, Invesco Ltd., Thoroughbred Financial Services LLC, Railway Pension Investments Ltd, Fisher Asset Management LLC and Jensen Investment Management Inc.. Company insiders that have bought Pfizer stock in the last two years include Pfizer Inc and Scott Gottlieb. View Insider Buying and Selling for Pfizer.

How do I buy shares of Pfizer?

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $36.88.

How big of a company is Pfizer?

Pfizer has a market capitalization of $203.99 billion and generates $53.65 billion in revenue each year. The biopharmaceutical company earns $11.15 billion in net income (profit) each year or $3.00 on an earnings per share basis. Pfizer employs 92,400 workers across the globe.View Additional Information About Pfizer.

What is Pfizer's official website?

The official website for Pfizer is http://www.pfizer.com/.

How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.


MarketBeat Community Rating for Pfizer (NYSE PFE)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  1,302 (Vote Outperform)
Underperform Votes:  850 (Vote Underperform)
Total Votes:  2,152
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe PFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/16/2019 by MarketBeat.com Staff

Featured Article: Is the QQQ ETF safe?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel